Compound J27 alleviates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease by targeting JNK
J27, as a potent JNK inhibitor, markedly reduced HFD-induced MASLD, suggesting it as a promising therapeutic candidate for this disease.
Authors
- Weiwei Zhu (ORCID: https://orcid.org/0000-0002-3275-1461)
- Jiaxi Ye (ORCID: https://orcid.org/0000-0001-6389-1056)
- Mengsha Lin
- Wu Luo (ORCID: https://orcid.org/0000-0003-3827-1159)
- Hui Dong (ORCID: https://orcid.org/0000-0003-4771-0846)
- Leiming Jin
- Yaqian Cui
- Yongqiang Xiong (ORCID: https://orcid.org/0000-0003-4175-0097)
- Xiang Hu (ORCID: https://orcid.org/0000-0003-1536-0036)
- Qianhui Zhang (ORCID: https://orcid.org/0000-0002-1777-3398)
- Guang Liang (ORCID: https://orcid.org/0009-0005-1603-3223)
- Ao Wang (ORCID: https://orcid.org/0009-0000-5261-0511)
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1016/j.intimp.2025.114570
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35